Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 28, 2014; 20(44): 16726-16733
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16726
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16726
Table 3 Adverse events n (%)
| Event | |
| Death, n | 0 |
| Drug Discontinuation due to AE | 6 (10) |
| Dose Modification due to AE | 8 (14) |
| Any life-threatening adverse event, n | 0 |
| Any serious adverse event | 2 (4) |
| Hematologic event Reduced neutrophil count < 750 per mm3 < 500 per mm3 | 14 (25) 8 (15) |
| Mean change in hemoglobin from baseline (g/dL) | |
| At wk 12 | -1.2 |
| At wk 24 | -2.2 |
| At wk 48 | -3.3 |
| Erythropoietin use | 20 (35) |
| Transfusion | 1 (1.8) |
| Common adverse event | |
| Nausea | 24 (43) |
| Anemia | 23 (41) |
| Dysgeusia | 20 (36) |
| Fatigue | 18 (32) |
| Rash | 6 (11) |
- Citation: Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol 2014; 20(44): 16726-16733
- URL: https://www.wjgnet.com/1007-9327/full/v20/i44/16726.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i44.16726